Research programme: anticancer therapeutics - Dekk-Tec/Tigris Pharmaceuticals

Drug Profile

Research programme: anticancer therapeutics - Dekk-Tec/Tigris Pharmaceuticals

Alternative Names: A 007 analogues - Tigris Pharmaceuticals; A-024; Sivifene analogues - Tigris Pharmaceuticals

Latest Information Update: 23 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Barbara Ann Karmanos Cancer Institute; Dekk-Tec
  • Developer Tigris Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 19 Oct 2005 Preclinical trials in Cancer in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top